TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$13.47 USD
-0.44 (-3.16%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $13.46 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TGTX 13.47 -0.44(-3.16%)
Will TGTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TGTX
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Company News for Feb 29, 2024
TGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know
Other News for TGTX
Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)
TG Therapeutics call volume above normal and directionally bullish
TG Therapeutics wins VA contract for Briumvi
TG Therapeutics contact with VA 'unequivocal win,' says JPMorgan
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)